These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17621876)

  • 1. Current status of tissue kallikrein inhibitors: importance in cancer.
    Bhoola KD; Misso NL; Naran A; Thompson PJ
    Curr Opin Investig Drugs; 2007 Jun; 8(6):462-8. PubMed ID: 17621876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
    Swedberg JE; de Veer SJ; Harris JM
    Biol Chem; 2010 Apr; 391(4):357-74. PubMed ID: 20180638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of human epidermal kallikrein 7 (hK7) synthesized directly in its native state in E. coli: insights into the atomic basis of its inhibition by LEKTI domain 6 (LD6).
    Fernández IS; Ständker L; Mägert HJ; Forssmann WG; Giménez-Gallego G; Romero A
    J Mol Biol; 2008 Apr; 377(5):1488-97. PubMed ID: 18329042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
    Swedberg JE; Nigon LV; Reid JC; de Veer SJ; Walpole CM; Stephens CR; Walsh TP; Takayama TK; Hooper JD; Clements JA; Buckle AM; Harris JM
    Chem Biol; 2009 Jun; 16(6):633-43. PubMed ID: 19549601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of commercial polyvalent proteinase inhibitors. Comparative analysis of their effect on kallikreins from different sources and trypsin].
    Iarovaia GA; Dotsenko VL; Agapova EI; Stepanian EP
    Vopr Med Khim; 1980; 26(6):832-7. PubMed ID: 6161484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of kallikrein-related peptidases: An overview.
    Masurier N; Arama DP; El Amri C; Lisowski V
    Med Res Rev; 2018 Mar; 38(2):655-683. PubMed ID: 28609548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the kallikrein-related peptidases for drug development.
    Sotiropoulou G; Pampalakis G
    Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and characterisation of blarinasin, a new tissue kallikrein-like protease from the short-tailed shrew Blarina brevicauda: comparative studies with blarina toxin.
    Kita M; Okumura Y; Ohdachi SD; Oba Y; Yoshikuni M; Nakamura Y; Kido H; Uemura D
    Biol Chem; 2005 Feb; 386(2):177-82. PubMed ID: 15843162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase inhibitors as anticancer agents.
    Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
    Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSIs described as most important finding in cancer-targeting research.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):617-8. PubMed ID: 12503199
    [No Abstract]   [Full Text] [Related]  

  • 11. Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7.
    Arama DP; Soualmia F; Lisowski V; Longevial JF; Bosc E; Maillard LT; Martinez J; Masurier N; El Amri C
    Eur J Med Chem; 2015 Mar; 93():202-13. PubMed ID: 25682203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of protease and protease inhibitors in cancer pathogenesis and treatment.
    Eatemadi A; Aiyelabegan HT; Negahdari B; Mazlomi MA; Daraee H; Daraee N; Eatemadi R; Sadroddiny E
    Biomed Pharmacother; 2017 Feb; 86():221-231. PubMed ID: 28006747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
    Mize GJ; Wang W; Takayama TK
    Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behavior of the kallikrein inhibitor against enzymes, 3. Behavior of the kallikrein inhibitor from bovine lung against proteases].
    Kraut H; Bhargava N
    Hoppe Seylers Z Physiol Chem; 1967 Nov; 348(11):1498-9. PubMed ID: 4231141
    [No Abstract]   [Full Text] [Related]  

  • 15. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
    Cereda V; Formica V; Menghi A; Pellicori S; Roselli M
    Expert Opin Investig Drugs; 2015; 24(7):929-47. PubMed ID: 25858813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.
    Sananes A; Cohen I; Shahar A; Hockla A; De Vita E; Miller AK; Radisky ES; Papo N
    J Biol Chem; 2018 Aug; 293(33):12663-12680. PubMed ID: 29934309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic inhibitors of human tissue kallikrein.
    Evans DM; Jones DM; Pitt GR; Ashworth D; De Clerck F; Verheyen F; Szelke M
    Immunopharmacology; 1996 May; 32(1-3):117-8. PubMed ID: 8796285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins.
    Rajapakse S; Ogiwara K; Takano N; Moriyama A; Takahashi T
    FEBS Lett; 2005 Dec; 579(30):6879-84. PubMed ID: 16337200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tissue kallikreins: the cancer biomarker family.
    Paliouras M; Borgono C; Diamandis EP
    Cancer Lett; 2007 Apr; 249(1):61-79. PubMed ID: 17275179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).
    Goettig P; Magdolen V; Brandstetter H
    Biochimie; 2010 Nov; 92(11):1546-67. PubMed ID: 20615447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.